Karam Takhar serves as Vice President, Corporate Development & Investor Relations at Skye Bioscience Inc., a San Diego-based biopharmaceutical company developing proprietary cannabinoid derivatives to treat disease with unmet need.
Prior to his role at Skye, Karam served as an Executive Director at Emerald Health Sciences where he led the first operation in Canada to harvest hemp for cannabinoid extraction. Subsequently he managed the Investor Relations program for Emerald’s portfolio of public and private cannabinoid science driven companies, during which time the portfolio raised more than $100M in capital. Prior to Emerald he has held various sales, marketing and business development roles at leading life science companies including, Promega Corporation and Stemcell Technologies.
Karam received his education from Simon Fraser University in British Columbia, Canada, where he earned his joint BSc (hons) in Molecular Biology-Biochemistry and Business Administration. After which he went on to conducted graduate studies at the British Columbia Cancer Research Center in the Department of Experimental Therapeutics as part the Pharmaceutical Sciences Program at the University of British Columbia.